HIF2 inactivation and tumor suppression with a tumor-directed RNA-silencing drug in mice and humans
Yuanqing Ma,Allison Joyce,Olivia Brandenburg,Faeze Saatchi,Christina Stevens,Alana Christie,Oluwatomilade Fatunde,Alyssa Macchiaroli,Layton Woolford,Qurratulain Yousuf,Jeffrey Miyata,Deyssy Carrillo,Oreoluwa Onabolu,Tiffani McKenzie,Akhilesh Mishra,Tanner Hardy,Wei He,Daniel Li,Alexander Ivanishev,Qing Zhang,Ivan Pedrosa,Payal Kapur,Thomas Schluep,James Hamilton,James Brugarolas,Vanina Toffessi. Tcheuyap,Quyen Do,So C. Wong,Steven B. Kanner
DOI: https://doi.org/10.1158/1078-0432.ccr-22-0963
IF: 13.801
2022-10-04
Clinical Cancer Research
Abstract:Purpose: HIF2α is a key driver of kidney cancer. Using a belzutifan analogue (PT2399), we previously showed in tumorgrafts (TGs) that ~50% of clear cell renal cell carcinomas (ccRCCs) are HIF2α dependent. However, prolonged treatment induced resistance mutations, which we also identified in humans. Here, we evaluated a tumor-directed, systemically-delivered, siRNA drug (siHIF2) active against wild-type and resistant mutant HIF2α. Experimental Design: Using our credentialed TG platform, we performed pharmacokinetic and pharmacodynamic analyses evaluating uptake, HIF2α silencing, target gene inactivation and anti-tumor activity. Orthogonal RNA-seq studies of siHIF2 and PT2399 were pursued to define the HIF2 transcriptome. Analyses were extended to a TG line generated from a study biopsy of a siHIF2 phase I clinical trial (NCT04169711) participant and the corresponding patient, an extensively pretreated individual with rapidly progressive ccRCC and paraneoplastic polycythemia likely evidencing a HIF2 dependency. Results: siHIF2 was taken up by ccRCC TGs, effectively depleted HIF2α, deactivated orthogonally-defined effector pathways (including Myc and novel E2F pathways), downregulated cell cycle genes and inhibited tumor growth. Effects on the study subject TG paralleled those in the patient, where HIF2α was silenced in tumor biopsies, circulating erythropoietin was downregulated, polycythemia was suppressed obviating the need for phlebotomies, and a partial response was induced. Conclusions: To our knowledge, this is the first example of functional inactivation of an oncoprotein and tumor suppression with a systemic, tumor-directed, RNA-silencing drug. These studies provide a proof-of-principle of HIF2α inhibition by RNA-targeting drugs in ccRCC and establish a paradigm for tumor-directed RNA-based therapeutics in cancer.
oncology